prof. dr. A.J.C. (Arjen) Slooter Full Professor
- Intensive Care Medicine
Arjen Slooter studied Medicine at the Vrije Universiteit, Amsterdam (1986-1994) and worked subsequently as a resident in Neurology in Sint Lucas Hospital, Amsterdam (1994). He was research fellow in Neuro-Epidemiology at the G.H. Sergievsky Center, Columbia University, New York (1996) and received a PhD in Epidemiology from Erasmus University, Rotterdam (1998), on a thesis on dementia. During his residency in Neurology in the UMC Utrecht (1999-2004), he became enthusiastic for Neurocritical Care. After a fellowship in Intensive Care Medicine (AMC Amsterdam, 2004-2006), he rejoined the UMC Utrecht where he is currently working as consultant neurologist-intensivist at the Department of Intensive Care Medicine. In 2016, he was appointed as Professor in Intensive Care Neuropsychiatry at Utrecht University.
The research focus of Arjen Slooter is on delirium and on neuropsychiatric outcome after anesthesia/surgery or critical illness. He currently works on an EEG-based device to detect delirium, functional connectivity in delirium, drug side-effects and delirium, postoperative delirium, and long-term outcome after ICU admission. He is President of the European Delirium Association and was chairman of the delirium section of the Society of Critical Care Medicine (SCCM) 2018 guideline on pain, agitation, delirium, early mobilization and sleep.
The clinical focus of Arjen Slooter is on Intensive Care of neurological- and neurosurgical patients, and on neurological complications of critical illness. He is responsible for training of ICU nurses, residents and fellows in Neuro-Intensive Care in the UMC Utrecht. Arjen lives with wife Barbara, daughter Pien (2001) and son Bas (2004) in beautiful Utrecht.
Delirium and (neuropsychiatric) outcome of critical illness
Most recent key publications
1. Van den Boogaard M, Slooter AJC, Brüggemann RJM, Schoonhoven L, Beishuizen A, Vermeijden JW, Pretorius D, de Koning J, Simons KS, Dennesen PJW, Van der Voort PHJ, Houterman S, van der Hoeven JG, Pickkers P; REDUCE Study Investigators. Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial. JAMA 2018;319:680-90 (IF=47.7).
2. Klein Klouwenberg PMC, Zaal IJ, Spitoni C, Ong DSY, van der Kooi AW, Bonten MJM, Slooter AJC, Cremer OL. The attributable mortality of delirium in critically ill patients. BMJ 2014;349:g6652 (IF=23.6).
3. Slooter AJC. Critical illness, delirium and cognitive impairment. Nature Rev Neurol 2013;9:666-7 (IF=20.3).
4. Van den Boogaard M, Pickkers P, Slooter AJ, Kuiper MA, Spronk PE, van der Voort PH, van der Hoeven JG, Donders R, van Achterberg T, Schoonhoven L. Development and validation of PRE-DELIRIC (PREdiction of DELIRium in ICu patients) delirium prediction model for intensive care patients: observational multicentre study. BMJ 2012;344:e420 (IF=23.6).
5. Van Eijk MMJ, Roes KCB, Honing MLH, Kuiper MA, Karakus A, van der Jagt M, Spronk PE, van Gool WA, van der Mast RC, Kesecioglu J, Slooter AJC. Rivastigmine does not decrease duration of delirium and may increase mortality in critically ill patients: a multicentre, double-blind, randomized, placebo-controlled add-on trial. Lancet 2010;376:1829-37 (IF=53.3).
Fellowship and Awards
‘Public private partnership to revolutionize delirium care in hospitals’. European Union (H2020-EIC-FTI-2018-2020-820555, co-applicant and principal clinical investigator, principal investigator).
‘Efficacy of haloperidol to decrease the burden of delirium in adult critically ill patients: a prospective randomised multicentre double-blind placebo-controlled clinical trial’. ZonMW GGG (80-84800-98-41 023, co-applicant).
‘Delirium Monitor: reducing the burden of delirium’. Technology Foundation STW, Take-off phase 2 (14066; co-applicant).
‘Objective delirium detection with an innovative EEG-based spot monitor’. European Union (H2020-PHC-12-2014-672974; co-applicant).
‘Delirium Monitor: reducing the burden of delirium’. Technology Foundation STW (2015-14066, principal investigator).
‘Objective delirium monitoring for routine critical care’. European Society of Intensive Care Medicine, Clinical Research Award (2014, principal investigator).
Annual Scientific Award, Society of Critical Care Medicine (2014, principal investigator).
EU-FP7 grant: ‘Biomarker development for postoperative cognitive impairment in the elderly’ (FP7-HEALTH-2013-Innovation-1, co-applicant).
Netherlands Heart Foundation: ‘Induced hypertension for treatment of delayed cerebral ischemia after aneurysmatic subarachnoid haemorrhage’ (2009, principal investigator).
Netherlands Brain Foundation: ‘Induced hypertension for treatment of delayed cerebral ischemia after aneurysmatic subarachnoid haemorrhage’ (2008, principal investigator).
ZonMW doelmatigheid: ‘Rivastigmine for delirium in Intensive Care patients, a multicentre, double-blind, randomised placebo-controlled add-on trial’ (ZonMW 170881003, principal investigator).